Subtype
Malignant Pharyngeal Neoplasm
CI-CAN-00003219Explore in graph →
411 active trials1 approved drugs2 evidence items
- NCIt
- C7545
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003219Explore in graph →
Clinical trials
1,255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03791944 | 3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma | completed | N/A | 100 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05860335 | Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT01819480 |
| Efficacy and Safety of TORS for SCCA |
| unknown |
| N/A |
| 110 |
| Katherine L FedderOTHER |
| 1 |
| Feb 9, 2024 |
| clinicaltrials |
| NCT05893810 | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis | unknown | Phase 3 | 176 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06182657 | The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | recruiting | — | 300 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05564286 | Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer | completed | Phase 3 | 116 | Shantou University Medical CollegeOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244394 | Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma | completed | — | 230 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05385926 | Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 34 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03708822 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04398524 | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | unknown | Phase 2 | 65 | ISA PharmaceuticalsINDUSTRY | 9 | Jan 16, 2024 | clinicaltrials |
| NCT05582590 | Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers | not yet recruiting | Phase 1 | 36 | NexImmune Inc.INDUSTRY | 0 | Jan 16, 2024 | clinicaltrials |
| NCT06032767 | Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning | unknown | — | 480 | Sun Yat-sen UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT02757222 | Dose Escalation Versus Standard in Laryngopharyngeal Cancers(INTELHOPE) | completed | N/A | 100 | Tata Medical CenterOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | recruiting | Phase 3 | 504 | Sun Yat-sen UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06167109 | NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma | recruiting | N/A | 60 | Chongqing University Cancer HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156891 | PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06136962 | Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life | unknown | — | 500 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06138483 | A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse | unknown | — | 267 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06121102 | Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain | unknown | N/A | 60 | National Cancer Institute, EgyptOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06129201 | Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging | unknown | — | 5,000 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04638465 | De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma | active not recruiting | — | 150 | Nebraska Methodist Health SystemOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03906058 | Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT06100081 | Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck(REFLECT) | unknown | N/A | 35 | University Medical Center GroningenOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06095167 | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC | not yet recruiting | Phase 3 | 476 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT01332682 | Resistance Training and Physical Functioning in Head and Neck Cancer Patients | completed | Phase 1 | 18 | University of Alabama at BirminghamOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05202626 | Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images | unknown | — | 100 | Chinese Academy of SciencesOTHER_GOV | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05918510 | Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus | recruiting | — | 142 | Regina Elena Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05368025 | Staying Connected: a Mobile Health Study With the Noona® and Mobili-T® Systems | completed | — | 65 | University of AlbertaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06055816 | Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05520814 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06039631 | Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer | recruiting | Phase 2 | 82 | Fudan UniversityOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04593186 | Magnifying NBI for Occult NPC | unknown | N/A | 246 | Chinese University of Hong KongOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06026878 | GNT Induction Treatment in Locally Advanced NPC | recruiting | Phase 3 | 228 | Air Force Military Medical University, ChinaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05949749 | A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC | unknown | — | 1,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT06016699 | Immunological Function After Radiation With Either Proton or Photon Therapy(PRO-IMMUNO) | unknown | — | 40 | University Medical Center GroningenOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05994170 | Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma(CTVp1-NPC) | recruiting | N/A | 454 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | terminated | Phase 1 / Phase 2 | 14 | Cullinan Therapeutics Inc.INDUSTRY | 5 | Aug 15, 2023 | clinicaltrials |
| NCT05992610 | Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy(iCHRTL) | unknown | N/A | 40 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT04156698 | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 51 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05981157 | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | unknown | Phase 2 | 27 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 8, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 23, 2024source: clinicaltrials